Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P. Offidani M, et al. Among authors: catarini m. Haematologica. 2006 Jan;91(1):133-6. Haematologica. 2006. PMID: 16434383 Clinical Trial.
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: catarini m. Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041. Clin Lymphoma Myeloma. 2008. PMID: 18854284
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Offidani M, Leoni P, Bringhen S, Corvatta L, Larocca A, Gentili S, Oliva S, Polloni C, Galieni P, Catarini M, Alesiani F, Mele A, Brunori M, Blasi N, Ferranti M, Visani G, Boccadoro M, Palumbo A. Offidani M, et al. Among authors: catarini m. Leuk Lymphoma. 2010 Aug;51(8):1444-9. doi: 10.3109/10428194.2010.486878. Leuk Lymphoma. 2010. PMID: 20496998
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P. Offidani M, et al. Among authors: catarini m. Leuk Lymphoma. 2011 May;52(5):776-85. doi: 10.3109/10428194.2011.555027. Epub 2011 Feb 21. Leuk Lymphoma. 2011. PMID: 21338282
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M, Polloni C, Cavallo F, Liberati AM, Ballanti S, Pulini S, Catarini M, Alesiani F, Corvatta L, Gentili S, Caraffa P, Boccadoro M, Leoni P, Palumbo A. Offidani M, et al. Among authors: catarini m. Leuk Lymphoma. 2012 Sep;53(9):1722-7. doi: 10.3109/10428194.2012.664844. Epub 2012 Mar 16. Leuk Lymphoma. 2012. PMID: 22335534 Clinical Trial.
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P. Offidani M, et al. Among authors: catarini m. Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13. Br J Haematol. 2009. PMID: 19036082 Free article. Clinical Trial.
26 results